Beam Therapeutics

Last updated
Beam Therapeutics Inc.
Company type Public
ISIN US07373V1052
Industry Biotechnology
Founded2017;8 years ago (2017)
Founders
Headquarters Cambridge, Massachusetts, U.S.
Key people
  • John Evans (CEO)
  • Giuseppe Ciaramella (CSO)
Number of employees
341 (December 31, 2021) [1]
Website beamtx.com

Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks. [2] [3]

Contents

History

Founded in 2017, the company traces its origins to the Broad Institute of the Massachusetts Institute of Technology and Harvard University. Co-founders include David R. Liu and Feng Zhang. [4] Prior to its IPO, the company raised nearly $1 billion in venture capital from investors. In a February 2020 IPO, the company raised $180 million. [5]

In January 2022, Pfizer and Beam Therapeutics announced a collaboration to develop therapies for rare diseases using CRISPR. [6] [7]

See also

References

  1. ↑ "Beam Therapeutics Inc. FORM 10-K". U.S. Securities and Exchange Commission . Retrieved 14 December 2022.
  2. ↑ "Why Beam Therapeutics Climbed 64.5% in June". NASDAQ. Archived from the original on 2021-08-07.
  3. ↑ Sterling, John (2021-07-15). "Base Editing Shows Promise as Common Inherited Lung and Liver Disease Therapy". GEN - Genetic Engineering and Biotechnology News. Retrieved 2021-08-07.
  4. ↑ Isaacson, Walter (2021). The Code Breaker. Simon & Schuster. pp. 461–462. ISBN   978-1-9821-1585-2.
  5. ↑ Dunn, Andrew. "Investors are betting billions that cutting-edge cures can upend how we treat heart disease and transform pharma". Business Insider. Retrieved 2021-08-07.
  6. ↑ "Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases". Pfizer.
  7. ↑ Alpert, Bill. "Pfizer and Beam Partner to Develop Treatments for 3 Genetic Diseases". www.barrons.com. Retrieved 2022-02-04.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.